Empa-REG outcome eligibility and preventable cardiovascular events in the US population: an analysis of the national health and nutrition examination survey
Abstract
The EMPA-REG OUTCOME trial recently demonstrated in persons with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) the efficacy of empagliflozin in reducing CVD events, as well as heart failure hospitalizations, cardiac and total mortality. The potential impact of EMPA-REG
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.